Find a Clinical Trial

Is a clinical trial right for you? Search our database to find studies for which you may be eligible.

Browse All Clinical Trials

Viewed View Trial

OPTIMICE-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

Study Type: Treatment

Phase: III

NCTID: NCT05812807

Principal Investigator: Priyanka Sharma

Viewed View Trial

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score

Study Type: Treatment

Phase: III

NCTID: NCT05879926

Principal Investigator: Lauren Nye

Viewed View Trial

Phase I/II Study of Cisplatin plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer

Study Type: Treatment

Phase: I/II

NCTID: NCT02393794

Principal Investigator:

Viewed View Trial

A Randomized, Multicenter, Double-Blind Phase III Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib For the Treatment of Patients with ER +, HER2 - Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease

Study Type: Treatment

Phase: III

NCTID: NCT04478266

Principal Investigator: Priyanka Sharma

Viewed View Trial

A PHASE III RANDOMIZED CLINICAL TRIAL OF PROTON CRANIOSPINAL IRRADIATION VERSUS INVOLVED-FIELD RADIOTHERAPY FOR PATIENTS WITH BREAST CANCER OR NON-SMALL CELL LUNG CANCER LEPTOMENINGEAL METASTASIS RADIATE-LM

Study Type: Treatment

Phase: III

NCTID: NCT06500481

Principal Investigator: Shane Stecklein

Viewed View Trial

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women with Obesity and Other Risk Factors for Breast Cancer

Study Type: Prevention

Phase: Feasibility/Pilot

NCTID: NCT06485089

Principal Investigator: Carol Fabian

Viewed View Trial

Prospective evaluation of outcomes for HER2-positive breast cancer PRO-HER2

Study Type: Other

Phase: N/A

NCTID: NCT06603597

Principal Investigator: Priyanka Sharma

Viewed View Trial

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Study Type: Treatment

Phase: III

NCTID: NCT05382286

Principal Investigator: Priyanka Sharma

Viewed View Trial

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician?s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PDL1 Agents in the Early Setting Whose Tumors do Express PD-L1

Study Type: Treatment

Phase: III

NCTID: NCT05382299

Principal Investigator: Priyanka Sharma

Viewed View Trial

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer DEBRA

Study Type: Treatment

Phase: III

NCTID: NCT04852887

Principal Investigator: Shane Stecklein